NO20074002L - Androgen reseptor-modulatorforbindelser og fremgangsmater - Google Patents

Androgen reseptor-modulatorforbindelser og fremgangsmater

Info

Publication number: NO20074002L
Authority: NO; Norway
Prior art keywords: methods; androgen receptor; receptor modulator; modulator compounds; compounds
Prior art date: 2005-06-17

Application number

NO20074002A

Other languages

English (en)

Norwegian (no)

Inventor

Lin Zhi

Bijan Pedram

Cornelis A Van Oeveren

Shuo Zhao

Yixing Shen

Original Assignee

Ligand Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-06-17

Filing date

2007-08-01

Publication date

2008-03-10

2007-08-01 Application filed by Ligand Pharm Inc filed Critical Ligand Pharm Inc

2008-03-10 Publication of NO20074002L publication Critical patent/NO20074002L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Reproductive Health (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Obesity (AREA)
Gynecology & Obstetrics (AREA)
Immunology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Pregnancy & Childbirth (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Anesthesiology (AREA)
Oncology (AREA)
Pulmonology (AREA)

NO20074002A 2005-06-17 2007-08-01 Androgen reseptor-modulatorforbindelser og fremgangsmater NO20074002L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US69189105P	2005-06-17	2005-06-17
PCT/US2006/023111 WO2006138347A2 (en)	2005-06-17	2006-06-12	Androgen receptor modulator compounds and methods

Publications (1)

Publication Number	Publication Date
NO20074002L true NO20074002L (no)	2008-03-10

Family

ID=37546607

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20074002A NO20074002L (no)	2005-06-17	2007-08-01	Androgen reseptor-modulatorforbindelser og fremgangsmater

Country Status (14)

Country	Link
US (2)	US8193357B2 (es)
EP (1)	EP1891067B1 (es)
JP (1)	JP5199079B2 (es)
KR (1)	KR101293935B1 (es)
CN (1)	CN101137655A (es)
AR (2)	AR054783A1 (es)
AU (1)	AU2006259474B2 (es)
BR (1)	BRPI0609191B8 (es)
CA (1)	CA2598216C (es)
IL (1)	IL185003A (es)
MX (1)	MX2007009784A (es)
NO (1)	NO20074002L (es)
NZ (1)	NZ560354A (es)
WO (1)	WO2006138347A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7026484B2 (en) *	2001-02-23	2006-04-11	Ligand Pharmaceuticals Incorporated	Tricyclic androgen receptor modulator compounds and methods
US8519158B2 (en)	2004-03-12	2013-08-27	Ligand Pharmaceuticals Incorporated	Androgen receptor modulator compounds and methods
AU2006259474B2 (en)	2005-06-17	2011-10-27	Ligand Pharmaceuticals Incorporated	Androgen receptor modulator compounds and methods
KR101595238B1 (ko)	2007-12-21	2016-02-18	리간드 파마슈티칼스 인코포레이티드	선택적 안드로겐 수용체 조절제(ｓａｒｍ) 및 이의 용도
AR072297A1 (es)	2008-06-27	2010-08-18	Novartis Ag	Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
EA028572B1 (ru)	2011-03-10	2017-12-29	Ксерис Фармасьютикалс, Инк.	Стабильная композиция для парентеральной инъекции и способы ее получения и использования
US9125805B2 (en) *	2012-06-27	2015-09-08	Xeris Pharmaceuticals, Inc.	Stable formulations for parenteral injection of small molecule drugs
WO2014043278A1 (en)	2012-09-11	2014-03-20	Visa International Service Association	Cloud-based virtual wallet nfc apparatuses, methods and systems
AU2015300944B2 (en)	2014-08-06	2019-07-11	Xeris Pharmaceuticals, Inc.	Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
CN104856996B (zh) *	2015-04-27	2018-01-05	南京舒鹏生物科技有限公司	吡咯喹啉醌、其衍生物和/或盐新的药用用途以及药用组合物
US9649364B2 (en)	2015-09-25	2017-05-16	Xeris Pharmaceuticals, Inc.	Methods for producing stable therapeutic formulations in aprotic polar solvents
US11590205B2 (en)	2015-09-25	2023-02-28	Xeris Pharmaceuticals, Inc.	Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
EP4233859A1 (en) *	2017-03-29	2023-08-30	Purdue Research Foundation	Inhibitors of kinase networks and uses thereof
KR102646865B1 (ko)	2017-06-02	2024-03-11	엑스에리스 파머수티클스, 인크.	침전 방지 저분자 약물 제제
WO2022006365A2 (en) *	2020-07-02	2022-01-06	Purdue Research Foundation	Tetrahydro-3h-pyrazolo quinolone and tetrahydro-3h-pyrrolo[3,2-f]quinoline-containing compounds and uses thereof
TW202214632A (zh) *	2020-07-27	2022-04-16	大陸商江蘇恆瑞醫藥股份有限公司	吲哚稠環類衍生物、其製備方法及其在醫藥上的應用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3710795A (en) *	1970-09-29	1973-01-16	Alza Corp	Drug-delivery device with stretched, rate-controlling membrane
US3847988A (en) *	1971-12-23	1974-11-12	Schering Corp	Substituted imidates
GB1429184A (en) *	1972-04-20	1976-03-24	Allen & Hanburys Ltd	Physically anti-inflammatory steroids for use in aerosols
US4044126A (en) *	1972-04-20	1977-08-23	Allen & Hanburys Limited	Steroidal aerosol compositions and process for the preparation thereof
USRE28819E (en) *	1972-12-08	1976-05-18	Syntex (U.S.A.) Inc.	Dialkylated glycol compositions and medicament preparations containing same
US3919238A (en)	1973-06-06	1975-11-11	Morton Norwich Products Inc	9-(Substituted amino)imidazo(4,5-f) quinolines
FR2329276A1 (fr) *	1975-10-29	1977-05-27	Roussel Uclaf	Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant
SU548608A1 (ru)	1975-07-16	1977-02-28	Московский Ордена Ленина И Ордена Трудового Красного Знамени Государственный Университет Им.М.В.Ломоносова	Способ получени замещенных пиррохинолинов
US4328245A (en) *	1981-02-13	1982-05-04	Syntex (U.S.A.) Inc.	Carbonate diester solutions of PGE-type compounds
US4410545A (en) *	1981-02-13	1983-10-18	Syntex (U.S.A.) Inc.	Carbonate diester solutions of PGE-type compounds
US4358603A (en) *	1981-04-16	1982-11-09	Syntex (U.S.A.) Inc.	Acetal stabilized prostaglandin compositions
US4409239A (en) *	1982-01-21	1983-10-11	Syntex (U.S.A.) Inc.	Propylene glycol diester solutions of PGE-type compounds
US4522811A (en) *	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE3372965D1 (en) *	1982-07-23	1987-09-17	Ici Plc	Amide derivatives
US5071773A (en) *	1986-10-24	1991-12-10	The Salk Institute For Biological Studies	Hormone receptor-related bioassays
US4981784A (en) *	1987-12-02	1991-01-01	The Salk Institute For Biological Studies	Retinoic acid receptor method
US5052558A (en) *	1987-12-23	1991-10-01	Entravision, Inc.	Packaged pharmaceutical product
US5033252A (en) *	1987-12-23	1991-07-23	Entravision, Inc.	Method of packaging and sterilizing a pharmaceutical product
WO1993022317A1 (en)	1992-05-01	1993-11-11	Kowa Co., Ltd.	Quinoline derivative or salt thereof and remedy for cardiac diseases containing the same
US5323907A (en) *	1992-06-23	1994-06-28	Multi-Comp, Inc.	Child resistant package assembly for dispensing pharmaceutical medications
EP1041071A1 (en)	1994-12-22	2000-10-04	Ligand Pharmaceuticals Incorporated	Methods for the preparation of coumarine derivatives
US5688810A (en) *	1994-12-22	1997-11-18	Ligand Pharmaceuticals Incorporated	Steroid receptor modulator compounds and methods
US6696459B1 (en) *	1994-12-22	2004-02-24	Ligand Pharmaceuticals Inc.	Steroid receptor modulator compounds and methods
EP1336600A3 (en)	1995-10-06	2004-07-07	Ligand Pharmaceuticals Incorporated	Dimer-selective RXR modulators and methods for their use
US6017924A (en) *	1996-06-27	2000-01-25	Ligand Pharmaceuticals Incorporated	Androgen receptor modulator compounds and methods
WO1999005161A1 (en)	1997-07-25	1999-02-04	Ligand Pharmaceuticals Incorporated	HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARη) GENE REGULATORY SEQUENCES AND USES THEREFOR
US6506766B1 (en) *	1998-02-13	2003-01-14	Abbott Laboratories	Glucocortiocoid-selective antinflammatory agents
US6380207B2 (en) *	1998-02-13	2002-04-30	Abbott Laboratories	Glucocortiocoid-selective antiinflammatory agents
US6001846A (en) *	1998-02-17	1999-12-14	Ligand Pharmaceuticals Incorporated	Process for the preparation of 1,2-dihydroquinolines
GB9819019D0 (en)	1998-09-01	1998-10-28	Cerebrus Ltd	Chemical compounds II
JP3390744B2 (ja) *	1998-09-22	2003-03-31	山之内製薬株式会社	シアノフェニル誘導体
US6566372B1 (en) *	1999-08-27	2003-05-20	Ligand Pharmaceuticals Incorporated	Bicyclic androgen and progesterone receptor modulator compounds and methods
AU778655B2 (en) *	1999-08-27	2004-12-16	Ligand Pharmaceuticals Incorporated	Androgen receptor modulator compounds and methods
DE60032780T2 (de) *	1999-10-14	2007-11-08	Kaken Pharmaceutical Co., Ltd.	Tetrahydroquinolin-derivate
DK1401801T3 (da) *	2000-08-24	2007-03-05	Univ Tennessee Res Foundation	Selektive androgenreceptormodulatorer og fremgangsmåder til anvendelse deraf
WO2002022585A1 (fr)	2000-09-14	2002-03-21	Kaken Pharmaceutical Co., Ltd.	Composes de tetrahydroquinoline
US7214690B2 (en) *	2001-02-23	2007-05-08	Ligand Pharmaceuticals Incorporated	Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods
US7026484B2 (en) *	2001-02-23	2006-04-11	Ligand Pharmaceuticals Incorporated	Tricyclic androgen receptor modulator compounds and methods
US6670386B2 (en) *	2001-07-31	2003-12-30	Bristol-Myers Squibb Company	Bicyclic modulators of androgen receptor function
GB0126036D0 (en)	2001-10-30	2001-12-19	Amedis Pharm Ltd	Silicon compounds
HK1055058A2 (en)	2002-10-11	2003-12-05	Ligand Pharm Inc	5-CYCLOALKENYL 5H-CHROMENO[3,4-f]QUINOLINE DERIVATIVES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS
JP4709759B2 (ja) *	2003-08-22	2011-06-22	リガンド・ファーマシューティカルズ・インコーポレイテッド	アンドロゲン受容体モジュレーター化合物としての６−シクロアミノ−２−キノリノン誘導体
US8519158B2 (en) *	2004-03-12	2013-08-27	Ligand Pharmaceuticals Incorporated	Androgen receptor modulator compounds and methods
AU2006259474B2 (en)	2005-06-17	2011-10-27	Ligand Pharmaceuticals Incorporated	Androgen receptor modulator compounds and methods
US20090227571A1 (en) *	2005-07-01	2009-09-10	Ligand Pharmaceuticals Incorporated	Androgen Receptor Modulator Compounds and Methods
WO2007075884A2 (en)	2005-12-21	2007-07-05	Ligand Pharmaceuticals Incorporated	Androgen receptor modulator compounds and methods
KR101595238B1 (ko) *	2007-12-21	2016-02-18	리간드 파마슈티칼스 인코포레이티드	선택적 안드로겐 수용체 조절제(ｓａｒｍ) 및 이의 용도

2006
- 2006-06-12 AU AU2006259474A patent/AU2006259474B2/en not_active Ceased
- 2006-06-12 KR KR1020077020058A patent/KR101293935B1/ko active IP Right Grant
- 2006-06-12 CN CNA2006800076998A patent/CN101137655A/zh active Pending
- 2006-06-12 NZ NZ560354A patent/NZ560354A/en not_active IP Right Cessation
- 2006-06-12 JP JP2008517047A patent/JP5199079B2/ja active Active
- 2006-06-12 BR BRPI0609191A patent/BRPI0609191B8/pt not_active IP Right Cessation
- 2006-06-12 US US11/883,247 patent/US8193357B2/en active Active
- 2006-06-12 EP EP06773124.0A patent/EP1891067B1/en active Active
- 2006-06-12 CA CA2598216A patent/CA2598216C/en not_active Expired - Fee Related
- 2006-06-12 MX MX2007009784A patent/MX2007009784A/es active IP Right Grant
- 2006-06-12 WO PCT/US2006/023111 patent/WO2006138347A2/en active Application Filing
- 2006-06-16 AR ARP060102591A patent/AR054783A1/es not_active Application Discontinuation
2007
- 2007-08-01 NO NO20074002A patent/NO20074002L/no not_active Application Discontinuation
- 2007-08-02 IL IL185003A patent/IL185003A/en not_active IP Right Cessation
2012
- 2012-03-06 US US13/385,802 patent/US8580811B2/en not_active Expired - Fee Related
2017
- 2017-03-10 AR ARP170100616A patent/AR107862A2/es unknown

Also Published As

Publication number	Publication date
WO2006138347A2 (en)	2006-12-28
BRPI0609191B8 (pt)	2021-05-25
US20090030027A1 (en)	2009-01-29
NZ560354A (en)	2010-10-29
AR107862A2 (es)	2018-06-13
JP5199079B2 (ja)	2013-05-15
AU2006259474B2 (en)	2011-10-27
IL185003A (en)	2015-06-30
US20120165362A1 (en)	2012-06-28
WO2006138347A3 (en)	2007-03-01
KR20080020592A (ko)	2008-03-05
EP1891067B1 (en)	2016-01-13
US20090264455A9 (en)	2009-10-22
US8193357B2 (en)	2012-06-05
EP1891067A2 (en)	2008-02-27
MX2007009784A (es)	2007-09-26
IL185003A0 (en)	2007-12-03
CA2598216A1 (en)	2006-12-28
BRPI0609191B1 (pt)	2020-10-13
AU2006259474A1 (en)	2006-12-28
CN101137655A (zh)	2008-03-05
BRPI0609191A2 (pt)	2010-03-02
US8580811B2 (en)	2013-11-12
JP2008543857A (ja)	2008-12-04
AR054783A1 (es)	2007-07-18
CA2598216C (en)	2014-04-08
KR101293935B1 (ko)	2013-08-08

Publication	Publication Date	Title
NO20074002L (no)	2008-03-10	Androgen reseptor-modulatorforbindelser og fremgangsmater
WO2007005887A3 (en)	2007-04-19	Androgen receptor modulator compounds, compositions and uses thereof
NO20090624L (no)	2009-04-20	Forbindelser som modulerer CB2 receptoren
NO20082285L (no)	2008-06-18	3-aminosyklopentankarboksamider som modulatorer av kjemokinreseptorer
WO2009082437A3 (en)	2009-09-03	Selective androgen receptor modulators (sarms) and uses thereof
NO20070487L (no)	2007-03-05	3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
MA32508B1 (fr)	2011-07-03	Composes organiques
NO20081160L (no)	2008-05-29	Benzimidazoltiofen forbindelser
WO2008131000A3 (en)	2008-12-18	7-substituted indole mcl-1 inhibitors
HK1097768A1 (en)	2007-07-06	Modified pyrimidine glucocorticoid receptor modulators
NO20075693L (no)	2008-02-07	Modulerende forbindelser av indolamin-2,3-dioksygenase og fremgangsmater for anvendelse av samme
NO20071619L (no)	2007-04-25	Fremgangsmate for fremstilling av indazol forbindelse
NO20081001L (no)	2008-03-25	Derivater av karboksamid som antagonister for muskarinisk reseptor
CL2011000087A1 (es)	2011-07-01	Compuestos derivados de heteroarilo sustituido, inhibidores de los receptores dgat1; composicion farmaceutica; y su uso para tratar la diabetes tipo ll y obesidad.
NO20065046L (no)	2006-11-06	Krystallinsk polymorf av bazedoksifenacetat
ATE459620T1 (de)	2010-03-15	Benzimidazolthiophenverbindungen als plk- modulatoren
EA200601895A1 (ru)	2007-04-27	3-(4-гетероарилциклогексиламино)циклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
MX2009006750A (es)	2009-06-30	Derivados de azaadamantano espirociclicos y metodos de uso.
NO20074277L (no)	2007-11-23	Kinnolinforbindelser og anvendelse derav som lever X reseptor modulatorer
WO2010057088A3 (en)	2010-10-14	Pyrrolidinyl modulators of nicotinic acetylcholine receptors
MX2010005704A (es)	2010-08-17	Derivados de cromano como modulares del trpv3.
DK1931636T3 (da)	2011-07-25	Isoquinoliner som IGF-1R-inhibitorer
EA200700365A1 (ru)	2007-06-29	Производные индол-2-карбоксамидина как антагонисты nmda рецептора
WO2007075884A3 (en)	2007-08-23	Androgen receptor modulator compounds and methods
NO20080553L (no)	2008-04-23	Azinyl-3-sulfonylindazolderivater som 5-hydroksytrypyamin-6 ligander

Legal Events

Date	Code	Title	Description
2011-01-31	FC2A	Withdrawal, rejection or dismissal of laid open patent application